Aims-To assess the extent of apoptosis in ovarian serous carcinoma and to examine possible relations between apoptosis, cell proliferation, p53 overexpression, and patient survival. Results-The mean apoptotic index was 1.3% (range 0.02-3.9%), the mean mitotic index was 0.4% (range 0.02-1.1%), and the mean Ki-67 labelling index was 16% (range 4-32%). There were significant correlations between the apoptotic and mitotic indices (p < 0.0205) and between the mitotic and Ki-67 labelling indices (p < 0.024). There was a significant correlation between a high apoptotic index and poor prognosis (p < 0.02). p53 was overexpressed in 16 cases but the extent of apoptosis and outcome were both independent of p53 status.
mean Ki-67 labelling index was 16% (range 4-32%). There were significant correlations between the apoptotic and mitotic indices (p < 0.0205) and between the mitotic and Ki-67 labelling indices (p < 0.024). There was a significant correlation between a high apoptotic index and poor prognosis (p < 0.02). p53 was overexpressed in 16 cases but the extent of apoptosis and outcome were both independent of p53 status.
Conclusions-These results suggest that regulation of apoptosis is an integral component of tumour cell kinetics in ovarian serous carcinoma, and that increased apoptosis is indicative of aggressive tumour growth. p53 expression did not correlate with altered apoptosis, but t-he possibility of an attenuated apoptotic response to subsequent DNA damage by anticancer agents is not excluded. Apoptosis is the highly conserved, genetically mediated process of selective cell deletion that occurs in embryogenesis, normal tissue homeostasis, and in many human diseases."2 Apoptosis is fundamental in tumour cell kinetics,' and susceptibility to apoptosis in untreated malignant tumours varies with tumour type. 3 The precise mechanisms that regulate tumour cell apoptosis in vivo are not understood fully but there are numerous endogenous and exogenous initiating factors including growth factor deprivation, viral infection, irradiation, and cytotoxic chemotherapy.' 4 In addition, apoptosis is subject to modulation by a large number of proto-oncogenes and tumour suppressor genes including c-myc, bcl-2, and p53. ' 5 Ovarian cancer is the leading cause of death in industrial countries among women with carcinomas of reproductive organs.6 Most patients present with advanced disease, management of which consists of debulking surgery followed by chemotherapy." The 30 cases of ovarian serous carcinom; the basis of this study. Two specimi available from two patients, each of w biopsies taken before and after chemotherapy. All other specimens were from untreated patients. Each tumour was assigned a pathological grade.
One or two haematoxylin and eosin stained sections were selected for evaluation of apoptosis, mitoses, and immunostaining. The apoptotic and mitotic indices were assessed as described previously.3 Briefly, the number of apoptotic tumour cells and mitoses in 10 high power (x40) fields (defined by a 1 mm index 100 square grid) was expressed as a percentage of the total number of tumour cells in these 10 fields. The edges of necrotic zones were avoided as were areas containing a high proportion of stromal cells.
Immunohistochemical staining for p53 and Ki-67 was performed using microwave induced antigen retrieval and a standard avidin-biotin complex method, using appropriate controls.'3 Sections were incubated in monoclonal mouse anti-p53-DO7 (Novacastra, Newcastle upon Tyne, UK; 1/50 dilution), overnight at 40C, and monoclonal rabbit anti-Ki-67 (Dako, High . Wycombe, Bucks, UK; 1/80 dilution), at room temperature for one hour. The colour reaction product was obtained with diaminobenzidine (seven minutes) and a light haematoxylin * counterstain. The p53 immunoreactivity was graded initially on a scale of 0-3 (0, all tumour cells negative; 1, < 1% (weakly) positive tumour cells; 2, multifocal aggregates of uniformly staining tumour cells; 3, diffuse positive staining throughout the tumour). Subsequently, grades 0 and 1 were considered to be p53 negative, and tumours graded as 2 or 3 were considered to be p53 positive.23 Cell proliferation was assessed by the Ki-67 labelling index, the percentage of Ki-67 positive cells Z , within the grid boundaries of 10 non-selected x40 objective fields. In situ end labelling was performed using an apoptosis detection kit (Apoptag; Oncor Inc, Gaithersburg, Missouri, USA). The principle of in situ end labelling is that terminal deoxynucleotidyl transferase (TdT) catalyses the binding of digoxygenin-dUTP to the 3-OH '-S ends of fragmented DNA in apoptotic cells.'4
Using antidigoxygenin peroxidase, and a methyl green counterstain, a brown colour reaction product identifies apoptotic nuclei. In situ end labelling was assessed semiquantitatively, using a five tiered scale. relatively small number of cases analysed. However, there was a close linear correlation between the apoptotic and mitotic indices (r = 0.4210; p < 0.0205).
The mean Ki-67 labelling index was 16% (range 4-32%). There was no correlation between the apoptotic and Ki-67 labelling indices, but there was a significant linear correlation between the mitotic and Ki-67 labelling indices (r = 0.4114; p < 0.0239).
In both cases where postchemotherapy specimens were examined, the apoptotic and mitotic indices and the Ki-67 labelling index were similar to the indices obtained from the original specimens.
IMMUNOHISTOCHEMICAL STAINING FOR P53
Nuclear staining for p53 was observed in 16 cases. Staining intensity was variable and was often maximal in peripheral tumour cells ( fig  4) . No cytoplasmic immunoreactivity was seen.
Apoptotic tumour cells were distributed in a similar pattern in p53 positive and p53 negative tumours. There was no correlation between p53 overexpression or grade of p53 immunoreactivity and the apoptotic, mitotic or Ki-67 labelling indices.
CLINICOPATHOLOGICAL CORRELATIONS
The extent of apoptosis correlated with survival time (median survival, 14 Our results indicate that there are close links between apoptosis and cell proliferation in ovarian serous carcinoma. We found a significant linear correlation between the apoptotic and mitotic indices, as reported recently in certain other tumour types.23 31-35 The Ki-67 labelling index, a measure of the percentage of proliferating cells, correlated significantly with the mitotic index. Furthermore, we observed that a high apoptotic index correlated very significantly with a poor prognosis in ovarian serous carcinoma. These findings suggest strongly that: regulation of apoptosis is an integral component of tumour cell kinetics, as in normal tissue homeostasis; and in certain tumour types, increased apoptosis is at least as significant as increased mitotic activity in reflecting aggressive tumour growth. Tumour growth is determined by the percentage of proliferating cells, cell cycle time, and the amount of cell loss.36 It has been suggested that apoptosis is in some way "defective" or inhibited in cancer.26 "" Data reported herein and elsewhere do not support the universal applicability of this concept: untreated carcinomas appear to display more, not less, apoptosis than normal tissues.23 335 However, we cannot exclude the possibility that in tumours showing increasing genomic instability affecting specific cell cycle regulatory genes, the tightly controlled process of apoptosis might become deregulated.
The p53 phosphoprotein is a transcription factor that controls numerous cellular genes, including those involved in regulation of the cell cycle.39 The p53 protein also induces growth arrest or apoptosis following DNA damage. In this study of ovarian serous carcinoma, the extent and distribution of apoptosis was independent of p53 overexpression, and p53 was not of prognostic significance. Ovarian carcinomas with p53 mutations are less susceptible to chemotherapy induced apoptosis, possibly because of an inability to transactivate the apoptosis inducing gene bax. 40 However, the role of p53 in regulating the extent of tumour cell apoptosis in vivo is not clear.4' Different p53 mutants have different biological effects.39 42 Even if all p53 mutant proteins were associated with diminished apoptosis inducing functions, p53 might not be required for fine tuning apoptosis in all untreated human tumours. With regard to the present study, it is accepted that immunostaining for p53 is not as specific as polymerase chain reaction-single strand conformational polymorphism analysis as a screening technique for p53 mutations, although there is good concordance."9 We cannot exclude the possibility that abnormal stabilisation of wildtype p53 protein in a minority of our p53 positive cases may have been associated with a higher apoptotic index. However, we are satisfied that even if this were so, the scatter of apoptotic indices in this series of ovarian serous carcinoma indicates that p53 abnormalities were not associated with alterations in the extent of apoptosis. In support of this, recent work on non-small cell lung carcinoma and leiomyosarcoma suggests that mutations in the "hot spot region" of p53 are not associated with attenuated apoptosis (O'Neill, Staunton, McMahon, Gaffney, unpublished data, 1997). The likely significance of p53 mutations in spontaneous human tumours is that the apoptosis response to subsequent DNA damage due to chemotherapy or radiation therapy might be reduced, as the experimental evidence suggests.
Does susceptibility to apoptosis in vivo predict an apoptotic response to radiation therapy or chemotherapy? Levine et 
